{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:33:21Z","timestamp":1792154001332,"version":"4.4.0"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100000996","name":"Department of Foreign Affairs and Trade, Australian Government","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000996","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","award":["OPP1129600"],"award-info":[{"award-number":["OPP1129600"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100020171","name":"Foreign, Commonwealth and Development Office","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100020171","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009099","name":"Irish Aid","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009099","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,4,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              TBI-223 is an oxazolidinone antibiotic under clinical development for the treatment of tuberculosis. Preclinical data indicate potent antituberculosis activity and a potentially improved safety profile over linezolid. In a single-ascending dose study and a multiple-ascending dose study in 114 healthy adults, TBI-223 was generally safe and well tolerated at single doses up to 2,600 mg and multiple doses up to 2,400 mg daily over 14 days. No deaths, serious or severe adverse events, or discontinuations resulting from adverse effects (other than COVID-19) occurred. Except for two instances of orthostatic tachycardia in the single-ascending dose (SAD) study that resolved, no clinically significant electrocardiogram changes were noted. Concentration-QTc modeling found significant relationships of QTc with concentrations of TBI-223 and its main metabolite. However, groups receiving TBI-223 experienced QTc &gt; 450 ms at a similar rate to those receiving placebo. TBI-223 exposures were nearly dose proportional. In the SAD study, TBI-223 exhibited a terminal half-life of 1.9\u20133.8 hours. Sustained-release tablets achieved a mean AUC\n              <jats:sub>0-inf<\/jats:sub>\n              of 70%\u201380% relative to immediate-release tablets, with more than 50% lower mean\n              <jats:italic>C<\/jats:italic>\n              <jats:sub>max<\/jats:sub>\n              . These results support further investigation of TBI-223 for the treatment of tuberculosis.\n            <\/jats:p>\n            <jats:sec>\n              <jats:title>CLINICAL TRIALS<\/jats:title>\n              <jats:p>\n                This study is registered with ClinicalTrials.gov as\n                <jats:related-object xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" document-id=\"NCT03758612\" document-id-type=\"clinical-trial-number\" source-id=\"ClinicalTrials.gov\" source-id-type=\"registry-name\" source-type=\"clinical-trials-registry\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03758612\">NCT03758612<\/jats:related-object>\n                and\n                <jats:related-object xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" document-id=\"NCT04865536\" document-id-type=\"clinical-trial-number\" source-id=\"ClinicalTrials.gov\" source-id-type=\"registry-name\" source-type=\"clinical-trials-registry\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04865536\">NCT04865536<\/jats:related-object>\n                .\n              <\/jats:p>\n            <\/jats:sec>\n          <\/jats:sec>","DOI":"10.1128\/aac.01542-24","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T13:03:56Z","timestamp":1741698236000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacokinetics, tolerability, and safety of TBI-223, a novel oxazolidinone, in healthy participants"],"prefix":"10.1128","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7383-2495","authenticated-orcid":true,"given":"Antonio","family":"Lombardi","sequence":"first","affiliation":[{"name":"Global Alliance for TB Drug Development","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran","family":"Pappas","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bruinenberg","sequence":"additional","affiliation":[{"name":"Vast Therapeutics","place":["Morrisville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0205-522X","authenticated-orcid":false,"given":"Jerry","family":"Nedelman","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajneesh","family":"Taneja","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Hickman","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Beumont","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Sun","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","volume-title":"Global tuberculosis report","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. 2023. Global tuberculosis report. World Health Organization, Geneva."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.05962.x"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01691-15"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201964"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1500286"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.12.0315"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00035114"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901814"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119430"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117166"},{"key":"e_1_3_4_12_2","volume-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. 2022. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. World Health Organization, Geneva."},{"key":"e_1_3_4_13_2","unstructured":"World Health Organization. 2022. Key updates to the treatment of drug-resistant tuberculosis: rapid communication June 2024. Geneva World Health Organization"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00035-23"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.9.3896-3902.2005"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200511243532123"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01655-22"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-018-0517-3"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50781-4"},{"key":"e_1_3_4_20_2","unstructured":"Pfizer. 2024. Zyvox label. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/021130s046 021131s044 021132s046lbl.pdf"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1338902"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15587"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.34141"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01723-10"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1023\/a:1026451721686"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01542-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01542-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T05:38:32Z","timestamp":1743745112000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01542-24"}},"subtitle":[],"editor":[{"given":"Sean","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,2]]}},"alternative-id":["10.1128\/aac.01542-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.01542-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"2024-10-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01542-24"}}